XTL Biopharmaceuticals Stock in Focus Following Nasdaq Delisting Deadline
XTL Biopharmaceuticals Ltd. shares ticked up Wednesday, with traders focused on the Nasdaq hearing process that may determine if the Israeli biotech will retain its U.S. listing. The stock traded at $2.44, rising 2.5% from its last close at $2.38. Nasdaq Composite barely changed, up 0.07%. S&P 500 edged up 0.02%. The company’s listing dispute was the driver, not the broad market.